Alcoholic Hepatitis: Current Challenges and Future Directions

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 4, 2014, Pages 555-564

  Singal, Ashwani K ^a   Kamath, Patrick S ^a   Gores, Gregory J ^a   Shah, Vijay H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Alcoholic hepatitis; Apoptosis; Liver injury; MELD

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; BACLOFEN; CORTICOSTEROID; ETANERCEPT; METHYLPREDNISOLONE; OXANDROLONE; PENTOXIFYLLINE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ARTICLE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; HUMAN; LIVER BIOPSY; LIVER TRANSPLANTATION;

ALCOHOLIC HEPATITIS; APOPTOSIS; LIVER INJURY; MELD;

ADRENAL CORTEX HORMONES; ALCOHOLISM; ANTI-INFLAMMATORY AGENTS; FREE RADICAL SCAVENGERS; HEPATITIS, ALCOHOLIC; HUMANS; LIVER TRANSPLANTATION; PENTOXIFYLLINE; TREATMENT OUTCOME;

EID: 84896089586     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.06.013     Document Type: Article

References (91)

1. Asrani S.K., Kamath P.S., Pedersen R., et al. Liver related mortality in the US is underestimated. Hepatology 2010, 52:408A.
2. Mandayam S., Jamal M.M., Morgan T.R. Epidemiology of alcoholic liver disease. Semin Liver Dis 2004, 24:217-232.
3. Bellentani S., Saccoccio G., Costa G., et al. Drinking habits as cofactors of risk for alcohol induced liver damage: the Dionysos Study Group. Gut 1997, 41:845-850.
4. Becker U., Deis A., Sorensen T.I., et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996, 23:1025-1029.
5. Frezza M., di Padova C., Pozzato G., et al. High blood alcohol levels in women: the role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. NEngl J Med 1990, 322:95-99.
6. Singal A.K., Anand B.S. Mechanisms of synergy between alcohol and hepatitis C virus. JClin Gastroenterol 2007, 41:761-772.
7. Trepo E., Gustot T., Degre D., et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. JHepatol 2011, 55:906-912.
8. Raynard B., Balian A., Fallik D., et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002, 35:635-638.
9. Singal A.K., Shah V.H. Alcoholic hepatitis: prognostic models and treatment. Gastroenterol Clin N Am 2011, 40:611-639.
10. Lucey M.R., Mathurin P., Morgan T.R. Alcoholic hepatitis. NEngl J Med 2009, 360:2758-2769.
11. Singal A.K., Kuo Y.F., Anand B.S. Hepatitis C virus infection inalcoholic hepatitis: prevalence patterns and impact on in-hospital mortality. Eur J Gastroenterol Hepatol 2012, 24:1178-1184.
12. Dunn W., Angulo P., Sanderson S., et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology 2006, 131:1057-1063.
13. Piano S.M., Rosi S., Cavallin M., et al. Urinary ethyl glucuronide improves the detection of alcohol consumption in liver transplant candidates and recipients. Hepatology 2012, 56:977A.
14. Sterneck M.R., Andresen G., Graeser C., et al. Screening for alcohol consumption in patients after liver transplantation using determination of ethyl glucuronide in urine and hair. Hepatology 2012, 56:281A.
15. Sterneck M.A., Staufer K., Schulz K.-H., et al. Ethyl glucuronide determination in hair for evaluation of long-term alcohol abstention in liver transplant candidates. Hepatology 2012, 56:493A.
16. Mendenhall C.L. Alcoholic hepatitis. Clin Gastroenterol 1981, 10:417-441.
17. Akriviadis E., Botla R., Briggs W., et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:1637-1648.
18. Lischner M.W., Alexander J.F., Galambos J.T. Natural history of alcoholic hepatitis: I-the acute disease. Am J Dig Dis 1971, 16:481-494.
19. Ceccanti M., Attili A., Balducci G., et al. Acute alcoholic hepatitis. JClin Gastroenterol 2006, 40:833-841.
20. Louvet A.A., Colin M., Lassailly G., et al. Patients with severe alcoholic hepatitis and hepatorenal syndrome need new therapeutic strategy. Hepatology 2012, 56:986A.
21. Hamid R., Forrest E.H. Is histology required for the diagnosis of alcoholic hepatitis? A review of published randomised controlled trials. Gut 2011, 60(Suppl 1):A233.
22. Lefkowitch J.H. Morphology of alcoholic liver disease. Clin Liv Dis 2005, 9:37-53.
23. Altamirano J., Miquel R., Katoonizadeh A., et al. Development and validation of a novel histological classification with prognostic value for alcoholic hepatitis. Hepatology 2011, 54:968A.
24. Maddrey W.C., Boitnott J.K., Bedine M.S., et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978, 75:193-199.
25. O'Shea R.S., Dasarathy S., McCullough A.J., et al. Alcoholic liver disease. Hepatology 2010, 51:307-328.
26. Sheth M., Riggs M., Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002, 2:2.
27. Srikureja W., Kyulo N.L., Runyon B.A., et al. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. JHepatol 2005, 42:700-706.
28. Zapata-Irrison L., Jurado-Nunez J., Altamirano-Gomez J. [Do MELD or Maddrey?: comparison of 2 forecasting models in patients with hepatitis toxic alcohol]. Revista de Gastroenterol de Mexico 2008, 73:57-62.
29. Dunn W., Jamil L.H., Brown L.S., et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005, 41:353-358.
30. Verma S., Ajudia K., Mendler M., et al. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig Dis Sci 2006, 51:1637-1643.
31. Jeong J.Y., Sohn J.H., Son B.K., et al. [Comparison of model for end-stage liver disease score with discriminant function and child-Turcotte-Pugh scores for predicting short-term mortality in Korean patients with alcoholic hepatitis]. Korean J Gastroenterol 2007, 49:93-99.
32. Forrest E.H., Evans C.D., Stewart S., et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005, 54:1174-1179.
33. Dominguez M., Rincon D., Abraldes J.G., et al. Anew scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008, 103:2747-2756.
34. Forrest E.H., Morris A.J., Stewart S., et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007, 56:1743-1746.
35. Louvet A., Naveau S., Abdelnour M., et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007, 45:1348-1354.
36. Singal A.K., Sagi S., Kuo Y.F., et al. Impact of hepatitis C virus infection on the course and outcome of patients with acute alcoholic hepatitis. Eur J Gastroenterol Hepatol 2011, 23:204-209.
37. Pandya P.K., Rao G., Weinman S.A. Impact of hepatitis C infection on survival in alcoholic hepatitis. Hepatology 2010, 52:672a-673a.
38. Thuluvath P.J., Nguyen G.C. Impact of Hcv and hepatic encephalopathy on the outcome of patients admitted with alcoholic hepatitis. Hepatology 2010, 52:1114A.
39. Potts J.G., Heneghan M.A., Verma S. Long term outcome in severe alcoholic hepatitis. Hepatology 2012, 56:985A.
40. Altamirano J., Higuera-de laTijera F., Duarte-Rojo A., et al. The amount of alcohol consumption negatively impacts short-term mortality in Mexican patients with alcoholic hepatitis. Am J Gastroenterol 2011, 106:1472-1480.
41. Yam F.G., Groessl E.J., Lau J.W., et al. Quality of care and predictors of readmission in hospitalized patients with alcoholic liver disease care in two academic medical centers. Hepatology 2012, 56:947A.
42. Chung T., Martin C.S., Winters K.C. Diagnosis, course, and assessment of alcohol abuse and dependence in adolescents. Recent Dev Alcoholism 2005, 17:5-27.
43. Addolorato G., Leggio L., Ferrulli A., et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007, 370:1915-1922.
44. Heydtmann M. The GABA-B agonist Baclofen improves alcohol consumption, psychometrics and may have effect on hospital admission rates in patients with alcoholic liver disease. Hepatology 2012, 56:1932A.
45. Garbutt J.C., Kampov-Polevoy A.B., Gallop R., et al. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010, 34:1849-1857.
46. Singal A.K., Charlton M.R. Nutrition in alcoholic liver disease. Clin Liv Dis 2012, 16:805-826.
47. Cordoba J., Lopez-Hellin J., Planas M., et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. JHepatol 2004, 41:38-43.
48. Singal A.K., Walia I., Singal A., et al. Corticosteroids and pentoxifylline for the treatment of alcoholic hepatitis: current status. World J Hepatol 2011, 3:205-210.
49. Mathurin P., O'Grady J., Carithers R.L., et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011, 60:255-260.
50. O'Shea R., Kinnard M.F., Umar N., et al. Treatment of alcoholic hepatitis (AH) in clinical practice. Gastroenterology 2009, 136:830A.
51. Singal A., Singal A., Jampana S., et al. Management of alcoholic hepatitis in the presence of concomitant hepatitis C virus infection: a survey of practising gastroenterologists and hepatologists. Am J Gastroenterol 2011, 106. S109-S.
52. Freyssinet M.A.I., Mosnier J.-F., Feray C., et al. Bilirubin evolution before corticosteroid has a major prognostic value in severe alcoholic hepatitis. Hepatology 2012, 56:963A.
53. Louvet A.A., Colin M., Lassailly G., et al. Spontaneous improvement of liver function is not a strong predictor of outcome in patients with severe alcoholic hepatitis treated with corticosteroids. Hepatology 2012, 56:981A.
54. Louvet A., Wartel F., Castel H., et al. Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor. Gastroenterology 2009, 137:541-548.
55. De B.K., Gangopadhyay S., Dutta D., et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009, 15:1613-1619.
56. Whitfield K., Rambaldi A., Wetterslev J., et al. Pentoxifylline foralcoholic hepatitis. Cochrane Database Syst Rev 2009, CD007339.
57. Lebrec D., Thabut D., Oberti F., et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010, 138:1755-1762.
58. Thiele M.A., Krag A., Gluud L.L. No additional effect of adding pentoxifylline to corticosteroids in severe alcoholic hepatitis: meta-analyses of randomized controlled trials. Hepatology 2012, 56:961A.
59. Louvet A., Diaz E., Dharancy S., et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. JHepatol 2008, 48:465-470.
60. Naveau S., Chollet-Martin S., Dharancy S., et al. Adouble-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004, 39:1390-1397.
61. Boetticher N.C., Peine C.J., Kwo P., et al. Arandomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008, 135:1953-1960.
62. Akerman P., Cote P., Yang S.Q., et al. Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am J Physiol 1992, 263:G579-G585.
63. Singal A.K., Jampana S.C., Weinman S.A. Antioxidants as therapeutic agents for liver disease. Liv Int 2011, 31:1432-1448.
64. Nguyen-Khac E., Thevenot T., Piquet M.A., et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. NEngl J Med 2011, 365:1781-1789.
65. Mendenhall C.L., Anderson S., Garcia-Pont P., et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. NEngl J Med 1984, 311:1464-1470.
66. Choi G., Runyon B.A. Alcoholic hepatitis: a clinician's guide. Clin Liv Dis 2012, 16:371-385.
67. Morris J.M., Dickson S., Neilson M., et al. Granulocytapheresis in the treatment of severe alcoholic hepatitis: a case series. Eur J Gastroenterol Hepatol 2010, 22:457-460.
68. Jalan R., Sen S., Steiner C., et al. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. JHepatol 2003, 38:24-31.
69. Sen S., Mookerjee R.P., Cheshire L.M., et al. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. JHepatol 2005, 43:142-148.
70. Singal A.K., Duchini A. Liver transplantation in acute alcoholic hepatitis: current status and future development. World J Hepatol 2011, 3:215-218.
71. Vanlemmens C., Di Martino V., Milan C., et al. Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial. Ann Intern Med 2009, 150:153-161.
72. McCallum S., Masterton G. Liver transplantation for alcoholic liver disease: a systematic review of psychosocial selection criteria. Alcohol Alcohol 2006, 41:358-363.
73. DiMartini A., Day N., Dew M.A., et al. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liv Transpl 2006, 12:813-820.
74. Cannesson A.D., Pageaux G.-P., Boleslawski E., et al. Prevalence and natural history of recurrent alcoholic cirrhosis after liver transplantation. Hepatology 2012, 56:506A.
75. Mathurin P., Moreno C., Samuel D., et al. Early liver transplantation for severe alcoholic hepatitis. NEngl J Med 2011, 365:1790-1800.
76. Singal A.K., Bashar H., Anand B.S., et al. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database. Hepatology 2012, 55:1398-1405.
77. Bjarnason I., Peters T.J., Wise R.J. The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet 1984, 1:179-182.
78. Vlachogiannakos J., Saveriadis A.S., Viazis N., et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 2009, 29:992-999.
79. Rasaratnam B., Kaye D., Jennings G., et al. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis: a randomized trial. Ann Intern Med 2003, 139:186-193.
80. Kalambokis G.N., Mouzaki A., Rodi M., et al. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia. Liv Int 2012, 32:467-475.
81. Vlachogiannakos J., Viazis N., Vasianopoulou P., et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. JGastroenterol Hepatol 2013, 28:450-455.
82. Stadlbauer V., Mookerjee R.P., Hodges S., et al. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. JHepatol 2008, 48:945-951.
83. Kirpich I.A., Solovieva N.V., Leikhter S.N., et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008, 42:675-682.
84. Suk K.S., Kim Y.D., Cheon G.J., et al. Effects of probiotics [cultured lactobacillus subtilis/streptococcus fecium] in the treatment of alcoholic hepatitis: a randomized controlled multicenter study. Hepatology 2012, 56:590A.
85. Patouraux S., Bonnafous S., Voican C.S., et al. The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PloS One 2012, 7:e35612.
86. Tirnitz-Parker J.E., Viebahn C.S., Jakubowski A., et al. Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology 2010, 52:291-302.
87. Colmenero J., Bataller R., Sancho-Bru P., et al. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology 2007, 132:687-697.
88. Kammuller M.E. Recombinant human interleukin-6: safety issues of a pleiotropic growth factor. Toxicology 1995, 105:91-107.
89. Ki S.H., Park O., Zheng M., et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology 2010, 52:1291-1300.
90. Kubes P., Mehal W.Z. Sterile inflammation in the liver. Gastroenterology 2012, 143:1158-1172.
91. Gao B. Hepatoprotective and anti-inflammatory cytokines inalcoholic liver disease. JGastroenterol Hepatol 2012, 27(Suppl2):89-93.